The Effects of EXOPULSE Mollii Suit on Motor Functions in Patients With Stroke (EXOSTROKE 2)"
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Balance using Berg Balance Scale (BBS)
研究概览
简要总结
The goal of this clinical trial is to demonstrate the improvement of motor functions related symptoms in patients with stroke and spasticity using Exopulse Mollii suit stimulation.
The main questions it aims to answer are:
to evaluate the short-term impact of EXOPULSE Mollii suit on balance in adult patients with stroke and suffering from spasticity.
to assess the effects of Exopulse Mollii suit on spasticity, mobility, pain, fatigue and QoL.
.
Participants will participate in:
One baseline visit for inclusion during which the patient will undergo the first session (active or sham) along with evaluations (before and after the session) One visit after two weeks during which the patient will undergo the second session (active or sham) along with evaluations (before and after the session) One visit after two weeks of the second stimulation condition; the patients will undergo a third evaluation and receive the EXOPULSE Mollii Suit for the four-week open label phase and will use the suit at home for an active stimulation session every other day for four weeks.
One visit at the end of the open label phase to perform the fourth and last evaluation and return the EXOPULSE Mollii suit.
Researchers will compare both Active and Sham groups to demonstrate the improvement of motor functions related symptoms in patients with stroke and spasticity using Exopulse Mollii suit.
详细描述
The study is a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and stroke related symptoms following a single session of "active" versus "sham" EXOPULSE Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of this phase (phase 1), a second phase of this trial, an open label phase, will be proposed for all patients to understand the effects of EXOPULSE Mollii suit employed over 4 weeks (a session every other day for a total of 14 sessions) on stroke related symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 75 years.
- •Having a clinical diagnosis of stroke since at least three months.
- •Being able to walk freely or with the need of support (modified Rankin score ≤ 4).
- •Able to understand verbal instructions.
- •Having spasticity with a score of at least 1+ on the MAS.
- •Having a BBS score ≤46 associated in the literature with a risk of fall.
排除标准
- •Being included in another research protocol during the study period.
- •Inability to undergo medical monitor for the study purposes due to geographical or social reasons.
- •Having a cardiac stimulator, a ventriculoperitoneal shunt, an intrathecal baclofen pump or other contraindications to using EXOPULSE Mollii suit.
- •Being pregnant.
- •Having a change in their stroke pharmacological therapy in the last three months.
- •Suffering from other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain).
- •Having a body mass index above 35 Kg/m
- •In case of the introduction of a medical device other than EXOPULSE Mollii suit during the study period.
- •Patients under juridical protection.
- •Prisoners.
结局指标
主要结局
Balance using Berg Balance Scale (BBS)
时间窗: To be assessed at week 8.
Balance will be assessed using the 14-item Berg Balance Scale (BBS) which has good psychometric properties in patients with stroke (concurrent validity, interrater reliability). The scale rates the balance using 56 points, with higher scores indicating better balance abilities. A score equal to or below 45 is commonly associated with risk of fall across the literature.
次要结局
- EQ-5D-5L: EuroQol 5 Dimensions 5 Levels Quality of Life Questionnaire(Two weeks after the second stimulation and 4 weeks later at the end of phase 2.)
- Muscle tone.(This to be assessed at baseline, then at week 2, week 4 and week 8.)
- Overall Clinical improvement(This to be assessed at baseline, then at week 2, and week 8.)
- Fall Risk(Two weeks after the second stimulation and 4 weeks later at the end of phase 2.)
- Weight(Baseline.)
- Visual Analog Score for spasticity.(This to be assessed at baseline, then at week 2, week 4 and week 8.)
- Height(Baseline)
- Body Mass Index (BMI)(Baseline)
- Visual Analog Score for pain.(This to be assessed at baseline, then at week 2, week 4 and week 8.)
- Blinding Questionnaire(This to be assessed at baseline, then at week 2.)
- Visual Analog Score for fatigue(This to be assessed at baseline, then at week 2, week 4 and week 8.)
- Time Up and Go (TUG)(This to be assessed at baseline, then at week 2, week 4 and week 8.)
研究者
Naji Joseph Riachi
Principal Investigator
Sheikh Shakhbout Medical City